Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

 590.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 592.00
  • 52 Week Low: 232.50
  • Currency: UK Pounds
  • Shares Issued: 120.18m
  • Volume: 0
  • Market Cap: £709.08m
  • RiskGrade: 125

OXB Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

1 Day Chart (08-09-2025)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -30.6% -13.9%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 5.5 4.4
Pr/Book 11.7  
Latest F'cast
Revenue 43.8% 25.8%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

OXB Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 87.73 (6.57) (7.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 142.80 19.88 22.77p 54.0 n/a n/a n/a 0.0%
31-Dec-22 139.99 (45.98) (41.29)p n/a n/a n/a n/a 0.0%
31-Dec-23 89.54 (188.53) (163.11)p n/a n/a n/a n/a 0.0%
31-Dec-24 128.80 (47.26) (41.75)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

OXB Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 162.04 (22.52) (28.87)p n/a n/a n/a n/a 0.0%
31-Dec-26 212.91 2.18 (10.84)p n/a n/a n/a n/a 0.0%
31-Dec-27 254.93 24.06 5.37p 109.8 n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

OXB Company Announcements

Total Voting Rights 01-Sep-2025 07:00 RNS
PDMR Dealings 22-Aug-2025 15:36 RNS
Holding(s) in Company 21-Aug-2025 10:24 RNS

OXB ShareCast News

RBC Capital Markets raises target price on OXB 26-Aug-2025 ShareCast
Oxford Biomedica raises £60m to bolster US capac... 15-Aug-2025 ShareCast
Oxford Biomedica agrees new four-year, $125m loa... 01-Aug-2025 ShareCast

OXB Top Newspaper Links

Need to know: Opec cuts forecast ... Tesco cuts ... 16-Aug-2008 Times
Need to know 10-May-2008 Times
DSG International may be losing its spark 12-Feb-2008 Telegraph

Latest OXB Director Deals

Traded Action Notifier PriceAmountValue
18-Aug-25 Sell Dame Kay Davies 500.40p 4,563 £22,833.25
15-Aug-25 Buy Roch Doliveux 449.75p 67,000 £301,332.50
11-Aug-25 Buy Dame Kay Davies 436.00p 4,563 £19,894.68

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

OXB Market Data

Currency UK Pounds
Share Price 590.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 592.00
52 Week Low 232.50
Volume 0
Shares Issued 120.18m
Market Cap £709.08m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average
17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average
Price Trend
84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average
86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average
Income Not Available
Growth
5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average
24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page